Article

Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer

2020-03-25

Abstract excerpt

<h4>ABSTRACT</h4> HER2 receptor tyrosine kinase (encoded by ERBB2 gene) is overexpressed in approximately 25% of all breast cancer tumors (known as HER2-positive breast cancers). Overexpression of HER2 causes overactivation of downstream receptor tyrosine kinase pathways including PI3K/Akt and MAPK pathways and is a poor prognosis factor in breast cancer. Tyrosine kinase inhibitor lapatinib and anti-HER2 monoclo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4cac5787-b38e-5577-9816-99189b44cb66
DOI: 10.1101/2020.03.24.006379

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancerDOI 10.1101/2020.03.24.006379Read

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)Semantic proximity Read

Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterationsSemantic proximity Read

EZH2 represses mesenchymal genes and upholds the epithelial state of breast carcinoma cellsSemantic proximity Read

E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.Semantic proximity Read

HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR.Semantic proximity Read

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family BromodomainsSemantic proximity Read

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.Semantic proximity Read

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin)Semantic proximity Read

FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.Semantic proximity Read

Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted TherapySemantic proximity Read

Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR–ERK independent of epithelial–mesenchymal transitionSemantic proximity Read

Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.Semantic proximity Read